Rabeprazole Promotes Vascular Repair and Resolution of Sepsis-Induced Inflammatory Lung Injury through HIF-1α

• Published in: Cells (Basel, Switzerland) Vol. 11; no. 9; p. 1425
• Main Authors: Evans, Colin E, Peng, Yi, Zhu, Maggie M, Dai, Zhiyu, Zhang, Xianming, Zhao, You-Yang
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.04.2022; MDPI
• Subjects: Animals; ARDS; Cytokines; Drugs; Edema; Endothelial cells; Endothelial Cells - metabolism; Endotoxemia; FDA approval; FoxM1; Gene expression; HIF-1α; High-throughput screening; Hypoxia; hypoxia-inducible factor; Hypoxia-inducible factor 1a; Inflammation; Ischemia; Laboratory animals; Leukocytes (neutrophilic); Lung Injury - metabolism; Lungs; Mice; Microvasculature; Permeability; Protein expression; Proteins; rabeprazole; Rabeprazole - metabolism; Rabeprazole - pharmacology; Rabeprazole - therapeutic use; Regulatory sequences; Respiratory Distress Syndrome; Sepsis; Sepsis - complications; Sepsis - drug therapy; Sepsis - genetics; United States > US; inflammation; HIF-1α; hypoxia-inducible factor; rabeprazole; FoxM1; ARDS; sepsis
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11091425

There are currently no effective treatments for sepsis and acute respiratory distress syndrome (ARDS). The repositioning of existing drugs is one possible effective strategy for the treatment of sepsis and ARDS. We previously showed that vascular repair and the resolution of sepsis-induced inflammatory lung injury is dependent upon endothelial HIF-1α/FoxM1 signaling. The aim of this study was to identify a candidate inducer of HIF-1α/FoxM1 signaling for the treatment of sepsis and ARDS. Employing high throughput screening of a library of 1200 FDA-approved drugs by using hypoxia response element (HRE)-driven luciferase reporter assays, we identified Rabeprazole (also known as Aciphex) as a top HIF-α activator. In cultured human lung microvascular endothelial cells, Rabeprazole induced HIF1A mRNA expression in a dose-dependent manner. A dose-response study of Rabeprazole in a mouse model of endotoxemia-induced inflammatory lung injury identified a dose that was well tolerated and enhanced vascular repair and the resolution of inflammatory lung injury. Rabeprazole treatment resulted in reductions in lung vascular leakage, edema, and neutrophil sequestration and proinflammatory cytokine expression during the repair phrase. We next used / Cre knockout mice and / Cre knockout mice to show that Rabeprazole promoted vascular repair through HIF-1α/FoxM1 signaling. In conclusion, Rabeprazole is a potent inducer of HIF-1α that promotes vascular repair and the resolution of sepsis-induced inflammatory lung injury via endothelial HIF-1α/FoxM1 signaling. This drug therefore represents a promising candidate for repurposing to effectively treat severe sepsis and ARDS.